Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors

Frontiers in Immunology

Immunology

Gang Ma¹  Li Zeng²  Kai Chen²  Qiao Zhou³ 

[1] Chengdu University of Traditional Chinese Medicine, Chengdu, China;Department of Rheumatology and Immunology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China;Department of Neurology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China;Department of Rheumatology and Immunology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China;Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China;

关键词: immune checkpoint inhibitor;    rheumatic immune-related adverse event;    bibliometric;    research trends;    VOSviewer;    CiteSpace;   

DOI  :  10.3389/fimmu.2023.1242336

 received in 2023-06-19, accepted in 2023-09-26,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundImmune checkpoint inhibitors (ICIs) has emerged as a popular cancer treatment approach. However, non-specific activation of T cells by ICIs can lead to immune-related adverse events (irAEs), including specific rheumatic manifestations. The study aimed to explore the current trend of ICIs associated rheumatic irAEs and summarize the knowledge structure through bibliometric methods.MethodsThe Web of Science Core Collection database (WoSCC) was selected for retrieving literature on ICIs associated rheumatic irAEs. To evaluate contributions from different countries/regions, institutions, journals, and authors, bibliometric analysis software, including VOSviewer and CiteSpace, as well as bibliometric online platforms, were utilized to construct and visualize bibliometric networks. Through the systematic review of this knowledge domain, future research directions were determined.ResultsIn This study, a total of 803 publications on ICIs-associated rheumatic irAEs were included for analysis. The distribution of these publications revealed two distinct growth phases: a stable phase between 2007 to 2015 followed by rapid growth from 2016 to 2020. The United States emerged as the top contributor in terms of publications, citations, and h-index, with the majority of leading institutions and funding agencies located there. Apart from government funding, pharmaceutical companies such as Bristol Myers Squibb and Merck Company also play a significant role in drug development and research. Analysis of keywords and citation bursts indicated that the initial burst was related to “monoclonal antibody,” “anti-CLTA4 antibody,” and “melanoma”. This was followed by a rise in interest related to “sarcoidosis,” “safety,” “inflammatory arthritis,” and “preexisting autoimmune.”ConclusionThis study summarized the global research trends concerning ICIs associated rheumatic irAEs. The findings can provide valuable insights into the current understanding of rheumatic irAEs, highlight the research trend and developments in the field. Future efforts should focus on developing classification criteria and guidelines, conducting prospective studies, investigating the mechanisms involved, and identifying biomarkers for prediction and monitoring of these events.

【 授权许可】

Unknown   
Copyright © 2023 Zeng, Ma, Chen and Zhou